Why the study?
Transseptal access for large sheaths may be hindered by tissue resistance against the sheath-dilator stepped interface.
Does the ExpanSure Large Access Transseptal Dilator reduce crossing force and facilitate left atrial access compared to a conventional transseptal system?
Does the ExpanSure Large Access Transseptal Dilator reduce crossing force and facilitate left atrial access compared to a conventional transseptal system?
The ExpanSure dilator reduces transseptal crossing force in a benchtop model and demonstrates procedural efficiency and safety in early clinical LAAC experience.
Answers are grounded in this paper and cite their sources.
Supports further development of low-force transseptal tools for LAAC; leaves open whether ExpanSure improves outcomes versus SL1 in larger trials.
BACKGROUND: Transseptal access for large sheaths may be encumbered by tissue resistance against the sheath-dilator stepped interface. The ExpanSure Large Access Transseptal Dilator (Baylis Medical) is designed as a single introducer and dilation device with a smooth sheath-dilator transition to support transseptal puncture. It may facilitate ease and efficiency of interatrial crossing. METHODS: This study experimentally evaluated the crossing force of ExpanSure relative to a conventional 8.5 F Swartz SL1 transseptal sheath and dilator in a benchtop septum model. Its ability to reduce the subsequent crossing force of a 14 F WATCHMAN delivery sheath was also tested. The clinical use of ExpanSure, including procedure time, was then validated in a series of left atrial appendage closure (LAAC) procedures. RESULTS: In a benchtop septum model (N = 12), less peak force (1.90 ± 0.08 N vs. 2.36 ± 0.09 N; p < .001) and overall work (17.3 ± 1.2 mJ vs. 28.0 ± 1.9 mJ; p < .001) were required to advance ExpanSure relative to a conventional SL1 transseptal sheath and dilator system. Peak force (2.34 ± 0.24 N vs. 2.65 ± 0.21 N; p < .003) and overall work (28.5 ± 3.9 mJ vs. 35.4 ± 2.1 mJ; p < .001) to advance a WATCHMAN sheath were also significantly lower after using ExpanSure than after using a conventional transseptal system. In 19 LAAC procedures, ExpanSure crossed the septum smoothly and integrated readily, which enabled efficient procedure completion (mean total procedure time 37.6 ± 13.5 min), with 100% success and no procedure-related complications. CONCLUSION: Experimental force measurements, combined with early clinical experience using ExpanSure, suggest that the tapered design with smooth transition without dilator-sheath step-up and the larger diameter, both facilitated ease and efficiency of interatrial crossing.
No takes yet. Share an insight, caveat, or question.
Inohara et al. (2021) studied Left atrial appendage closure (n=31). ExpanSure Large Access Transseptal Dilator vs. Conventional 8.5 F Swartz SL1 transseptal sheath and dilator was evaluated on Peak force to advance the dilator in a benchtop septum model (p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: